Drug Prices
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, 鈥淲hat drives health spending in the U.S. compared to other countries,鈥 does not provide a full picture on health care spending in the U.S. while also downplaying the immense role that drug costs play in鈥
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation鈥檚 costliest drugs. As part of the hearing, Committee Chairwoman Carolyn Maloney, D-N.Y., released additional staff reports describing repeated actions by drug鈥
The House Committee on Oversight and Reform launched a two-day hearing to examine pricing practices for some of the nation鈥檚 costliest drugs.
The Food and Drug Administration released a final rule allowing states, territories and Indian tribes to establish programs to import certain FDA-approved prescription drug and biological products from Canada.
President Trump issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human Services to test a 鈥渕ost-favored-nation鈥 pricing model for Part B, and some Part D, drugs.
Summary of President Trump鈥檚 executive order to address drug pricing via 鈥渕ost-favored-nation鈥 pricing model.
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana DeGette, D-Colo., and David McKinley, R-W.Va., along with Reps. Peter Welch, D-Vt., Greg Gianforte, R-Mont., Dusty Johnson, R-S.D., and鈥
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
AHA expresses concern regarding recent action taken by three major drug manufacturers 鈥 Eli Lilly and Co., Merck and Sanofi 鈥 to limit the distribution of certain 340B drugs to our hospital members.
President Trump signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health center insulin and EpiPen discounts; the importation and re-importation of prescription drugs from foreign countries; and drug manufacturer rebates and鈥